Aminopyrimidines, as inhibitors of both TBK1 and IKK, have been successfully tested in cancer cell lines [360]; GSK8612, developed by GlaxoSmithKline, inhibited IRF-3 phosphorylation and interferon-β secretion in vitro [361], while amlexanox, already approved for use in asthma and aphtous ulcer, is also a dual inhibitor of both IκB kinases and TBK1. Here, TBK1 is linked to cancer.